Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies
A Study of DCC-2618 in Patients with Advanced Malignancies
Sponsor:Deciphera Pharmaceuticals, LLC
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR7574
U.S. Government ID:NCT02571036
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information:

This research study will test an investigational study drug called DCC-2618. This research study will explore the following: find the highest safe dose of DCC-2618, see how often DCC-2618 should be given, see how well research participants with cancer tolerate DCC-2618, and evaluate if DCC-2618 is effective against cancer. Cancers include: brain tumors, spinal tumors, leukemia

Do You Qualify?
Are you 18 years or older?YesNo
Do you have a confirmed solid tumor or blood cancer?YesNo
Are you willing to undergo biopsies while on study?YesNo
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder

Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Phone: 212-342-5162